View in EDS HTML Full Text PDF Full Text

A patient with ALK‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative recurrence for 4 years by switching to ceritinib.

Saved in:
Bibliographic Details
Title: A patient with ALK‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative recurrence for 4 years by switching to ceritinib.
Authors: Matsumura, Yuki1 (AUTHOR) yukimatsumura1980@gmail.com, Inomata, Sho1 (AUTHOR), Yamaguchi, Hikaru1 (AUTHOR), Mine, Hayato1 (AUTHOR), Takagi, Hironori1 (AUTHOR), Watanabe, Masayuki1 (AUTHOR), Ozaki, Yuki1 (AUTHOR), Yamaura, Takumi1 (AUTHOR), Fukuhara, Mitsuro1 (AUTHOR), Muto, Satoshi1 (AUTHOR), Okabe, Naoyuki1 (AUTHOR), Hasegawa, Takeo1 (AUTHOR), Shio, Yutaka1 (AUTHOR), Suzuki, Hiroyuki1 (AUTHOR)
Source: Thoracic Cancer. Aug2021, Vol. 12 Issue 15, p2225-2228. 4p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:17597706
DOI:10.1111/1759-7714.14058